Female scientist filling vials

About Us
We Combat Disease Caused By
Insufficient Gene Expression

Company Overview

  • >50
  • 10
  • 4
  • Staff
  • Pipeline
  • Sites Globally

Our Vision

Improve Human Health by Innovation

Our Mission

Unleash the power of oligonucleotide therapeutics to tackle unmet medical needs.

Our Core Values

Integrity & Decency • Innovation & Persistence • Diligence & Perfection

Close up view of molecule

Our Story

Ractigen /răk’tijən/: RNA activates genes.

Ractigen Therapeutics is an early-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells.

Ractigen Therapeutics was founded in 2017 by the original pioneers in the field of RNAa to create a pipeline of new medicines to treat diseases caused by insufficient gene expression.

Scientific samples stacked up

Our Core Technology

Our core technology is based on a discovery made at the University of California San Francisco (UCSF) coined RNA activation (RNAa) that prompted a paradigm shift in the field of oligonucleotides therapeutics – targeted activation of gene expression using short non-coding RNA duplexes.

Learn More >

Headquarters

Our headquarters occupies a four-storied building in the Modern Industry Park of Life and Health Science of Rudong, Jiangsu, China.

We also occupy a growing laboratory space in the Zhangjiang High Technology Park in Shanghai, and have a 2000 sq. m. R&D center in the BioBay in Suzhou.

Our company is also launching our first international venture with a US site that is under construction within the Washington DC area.

Contact Us >

Our Team

Ractigen is led by a cohesive team of scientists, professionals, and biotech entrepreneurs with broad backgrounds in oligonucleotide research, chemistry, and drug development including the original core team of inventors behind the RNAa technology.

Meet the Team >

Funding

Ractigen Therapeutics has raised over 350 million RMB (~54M USD) in venture financing through series A and A+ funding rounds.

See Our Progress >